PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Pituitary adenylyl cyclase activating polypeptide, 38 amino acids (PACAP38) is a neuroprotective peptide.
• Methamphetamine (METH) causes significant neurotoxicity, particularly in the striatum.
• Understanding protective mechanisms against METH-induced damage is crucial for developing therapeutic strategies.

Purpose of the Study:

• To investigate the neuroprotective effects of PACAP38 against METH-induced neurotoxicity.
• To elucidate the mechanisms underlying PACAP38's protective actions.
• To determine if PACAP38 influences markers of oxidative stress and neuroinflammation.

Main Methods:

• Systemic administration of PACAP38 to mice prior to METH exposure.
• Assessment of striatal dopamine levels and markers of oxidative stress.
• Measurement of glial fibrillary acidic protein (GFAP) and glucose transporter 5 (GLUT5) as indicators of neuroinflammation.
• Evaluation of vesicular monoamine transporter 2 (VMAT2) expression and function.

Main Results:

• PACAP38 administration significantly attenuated METH-induced striatal dopamine loss.
• Reduced markers of oxidative stress and neuroinflammation (GFAP, GLUT5) were observed in PACAP38-treated mice.
• PACAP38 treatment led to increased expression and function of VMAT2.
• Protective effects were observed 28 days post-PACAP38 treatment, suggesting gene expression regulation.

Conclusions:

• PACAP38 demonstrates significant neuroprotective effects against METH-induced toxicity.
• The mechanism involves reducing oxidative stress, neuroinflammation, and importantly, upregulating VMAT2.
• PACAP38 signaling pathways represent a potential novel therapeutic target for dopamine storage disorders and METH-induced damage.